LifeMD price target raised to $13 from $11 at BTIG

BTIG raised the firm’s price target on LifeMD to $13 from $11 and keeps a Buy rating on the shares. The firm sees “no slowdown in demand” as LifeMD is currently adding over 400 new weight management patients each day, up from over 200 just a few months ago in Q4 of 2023, and at this pace, the company could add about 10,000 new members per quarter, which implies about $50M in new annualized revenue in 2024, the analyst tells investors in a research note.